![]() |
|
|
Vol. 53, Issue 4, 759-765, April 1998
Department of Pharmacology (P.G.S, J.A.K., J.M.E.) and
Glaxo
Institute of Applied Pharmacology (J.A.K.), University of Cambridge,
Cambridge, CB2 1QJ, United Kingdom
The molecular mechanisms underlying the internalization of G
protein-coupled receptors are still poorly understood. Normally agonists but not antagonists cause internalization (defined here as a
reduction in the number of receptors at the cell surface), suggesting a
functional relationship between agonist activity and internalization.
In this study we investigated the effects of eight muscarinic ligands
on the rate constants for endocytosis and recycling of m3 muscarinic
acetylcholine receptors in human SH-SY5Y neuroblastoma cells. We found
that there was a linear correlation between the intrinsic activity of
the ligand and its ability to increase the rate constant for
endocytosis, suggesting that the same active conformation of the
receptor is responsible for stimulating both second messenger
generation and receptor endocytosis. In contrast, the rate constant for
recycling did not depend on which agonist had triggered receptor
endocytosis, suggesting that recycling is a purely constitutive
process. Because receptor internalization depends on the rate constants
for both endocytosis and recycling, the relationship between
internalization and intrinsic activity is nonlinear. In particular,
mathematical modeling of receptor trafficking revealed that under
certain conditions very small (3% or less) increases in the rate
constant for endocytosis are sufficient to cause substantial receptor
internalization. An important implication of this analysis is that
extremely weak partial agonists (which may in practice be
indistinguishable from antagonists) may produce significant receptor
internalization.
This article has been cited by other articles:
![]() |
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, R. Cescato, D. A. Dewi, J. Rivier, J.-C. Reubi, and A. Schonbrunn Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs Mol. Pharmacol., July 1, 2005; 68(1): 90 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Thielemans, I. Depoortere, J. Perret, P. Robberecht, Y. Liu, T. Thijs, C. Carreras, E. Burgeon, and T. L. Peeters Desensitization of the Human Motilin Receptor by Motilides J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1397 - 1405. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Morris, R. R. Price, M. P. Smith, B. Lei, and D. A. Schwinn Cellular Trafficking of Human {alpha}1a-Adrenergic Receptors Is Continuous and Primarily Agonist-Independent Mol. Pharmacol., October 1, 2004; 66(4): 843 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Borgland, M. Connor, P. B. Osborne, J. B. Furness, and M. J. Christie Opioid Agonists Have Different Efficacy Profiles for G Protein Activation, Rapid Desensitization, and Endocytosis of Mu-opioid Receptors J. Biol. Chem., May 23, 2003; 278(21): 18776 - 18784. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun and M. C. Gershengorn Correlation between Basal Signaling and Internalization of Thyrotropin-Releasing Hormone Receptors: Evidence for Involvement of Similar Receptor Conformations Endocrinology, August 1, 2002; 143(8): 2886 - 2892. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Price, D. P. Morris, G. Biswas, M. P. Smith, and D. A. Schwinn Acute Agonist-mediated Desensitization of the Human alpha 1a-Adrenergic Receptor Is Primarily Independent of Carboxyl Terminus Regulation. IMPLICATIONS FOR REGULATION OF alpha 1aAR SPLICE VARIANTS J. Biol. Chem., March 8, 2002; 277(11): 9570 - 9579. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chavkin, J. P. McLaughlin, and J. P. Celver Regulation of Opioid Receptor Function by Chronic Agonist Exposure: Constitutive Activity and Desensitization Mol. Pharmacol., July 1, 2001; 60(1): 20 - 25. [Full Text] |
||||
![]() |
P. A. Zaki, D. E. Keith Jr., G. A. Brine, F. I. Carroll, and C. J. Evans Ligand-Induced Changes in Surface {micro}-Opioid Receptor Number: Relationship to G Protein Activation? J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1127 - 1134. [Abstract] [Full Text] |
||||
![]() |
K.-S. Min, X. Liu, J. Fabritz, J. Jaquette, A. N. Abell, and M. Ascoli Mutations That Induce Constitutive Activation and Mutations That Impair Signal Transduction Modulate the Basal and/or Agonist-stimulated Internalization of the Lutropin/Choriogonadotropin Receptor J. Biol. Chem., December 25, 1998; 273(52): 34911 - 34919. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Vilardaga, M. Frank, C. Krasel, C. Dees, R. A. Nissenson, and M. J. Lohse Differential Conformational Requirements for Activation of G Proteins and the Regulatory Proteins Arrestin and G Protein-coupled Receptor Kinase in the G Protein-coupled Receptor for Parathyroid Hormone (PTH)/PTH-related Protein J. Biol. Chem., August 31, 2001; 276(36): 33435 - 33443. [Abstract] [Full Text] [PDF] |
||||